Table 5.
Association of the five SNPs and DM/PM patients with ILD.
| Disease | Group | rs2205960 (TNFSF4) | rs844644 (TNFSF4) | rs844648 (TNFSF4) | rs6859219 (ANKRD55) | rs7731626 (ANKRD55) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Risk allele T (%) | P c | OR (95% CI) | Risk allele C (%) | P c | OR (95% CI) | Risk allele A (%) | P c | OR (95% CI) | Risk allele A (%) | P c | OR (95% CI) | Risk allele A (%) | P c | OR (95% CI) | ||
| DM | P versus N | 24.49 versus 28.98 | 0.350 | 0.79 (0.62–1.02) | 45.38 versus 46.78 | NS | 0.95 (0.76–1.18) | 46.41 versus 46.40 | NS | 1.00 (0.80–1.25) | 0.51 versus 0.19 | NS | 2.72 (0.30–24.37) | 6.54 versus 9.09 | 0.435 | 0.70 (0.46–1.06) |
| P versus C | 24.49 versus 26.33 | NS | 0.91 (0.75–1.09) | 45.38 versus 43.63 | NS | 1.07 (0.91–1.26) | 46.41 versus 44.57 | NS | 1.08 (0.92–1.27) | 0.51 versus 0.51 | NS | 1.01 (0.33–3.11) | 6.54 versus 9.77 | 0.030 | 0.65 (0.47–0.88) | |
| N versus C | 28.98 versus 26.33 | NS | 1.14 (0.93–1.41) | 46.78 versus 43.63 | 0.920 | 1.14 (0.94–1.37) | 46.40 versus 44.57 | NS | 1.08 (0.89–1.30) | 0.19 versus 0.51 | NS | 0.37 (0.05–2.85) | 9.09 versus 9.77 | NS | 0.92 (0.67–1.28) | |
|
| ||||||||||||||||
| PM | P versus N | 27.18 versus 27.08 | NS | 1.01 (0.72–1.40) | 45.64 versus 43.75 | NS | 1.08 (0.80–1.45) | 46.92 versus 44.35 | NS | 1.11 (0.83–1.49) | 0.51 versus 0.89 | NS | 0.57 (0.10–3.45) | 7.18 versus 8.93 | NS | 0.79 (0.46–1.35) |
| P versus C | 27.18 versus 26.33 | NS | 1.04 (0.82–1.33) | 45.64 versus 43.63 | NS | 1.09 (0.88–1.34) | 46.92 versus 44.57 | NS | 1.10 (0.89–1.36) | 0.51 versus 0.51 | NS | 1.01 (0.23–4.49) | 7.18 versus 9.77 | 0.515 | 0.71 (0.48–1.07) | |
| N versus C | 27.08 versus 26.33 | NS | 1.04 (0.80–1.34) | 43.75 versus 43.63 | NS | 1.01 (0.80–1.26) | 44.35 versus 44.57 | NS | 0.99 (0.79–1.25) | 0.89 versus 0.51 | NS | 1.77 (0.50–6.23) | 8.93 versus 9.77 | NS | 0.91 (0.61–1.35) | |
|
| ||||||||||||||||
| DM/PM | P versus N | 25.38 versus 28.24 | 0.750 | 0.86 (0.71–1.05) | 45.47 versus 45.60 | NS | 0.99 (0.83–1.19) | 46.58 versus 45.60 | NS | 1.04 (0.87–1.24) | 0.51 versus 0.46 | NS | 1.11 (0.31–3.94) | 6.75 versus 9.03 | 0.285 | 0.73 (0.53–1.01) |
| P versus C | 25.38 versus 26.33 | NS | 0.95 (0.81–1.12) | 45.47 versus 43.63 | NS | 1.08 (0.94–1.24) | 46.58 versus 44.57 | NS | 1.08 (0.94–1.25) | 0.51 versus 0.51 | NS | 1.01 (0.38–2.66) | 6.75 versus 9.77 | 0.015 | 0.67 (0.51–0.87) | |
| N versus C | 28.24 versus 26.33 | NS | 1.10 (0.93–1.31) | 45.60 versus 43.63 | NS | 1.08 (0.93–1.27) | 45.60 versus 44.57 | NS | 1.04 (0.89–1.22) | 0.46 versus 0.51 | NS | 0.91 (0.30–2.80) | 9.03 versus 9.77 | NS | 0.92 (0.70–1.20) | |
Bold values indicate statistical significance (Pc < 0.05); SNPs = single nucleotide polymorphisms; DM = dermatomyositis; PM = polymyositis; ILD = interstitial lung disease; Pc = P value corrected by Bonferroni method; OR = odds ratio; CI = confidence interval; Group P: patients with ILD; Group N: patients without ILD; Group C: healthy controls; Group P (DM: n = 390; PM: n = 195; DM/PM: n = 585); Group N (DM: n = 264; PM: n = 168; DM/PM: n = 432); Group C (n = 1280).